Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

"Offering Zepbound single-dose vials […] through another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved, and regulated obesity treatment ...

Ivim Health raises concern over US FDA’s arbitrary critical deadline comes; submits Amicus brief to fighting patient access to GLP-1 medications: Columbus, Ohio Thursday, Februa ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023 ... The restoration of Mounjaro’s availability coincides with increasing competition in the ...

Following a second day of stock market gains, investors looked forward to earnings reports from Eli Lilly and Amazon.

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Your local pharmacy might be the next front in Donald Trump’s trade war. The president has in recent weeks promised to impose tariffs on all foreign-made medications, a move intended to encourage drug ...

Patients who bought stockpiles of alternative GLP-1 drugs online aren't sure what to do with them after learning that the ...

“You run the risk of raising prices without any of the quality or availability benefits ... makes its weight loss and diabetes medications Zepbound and Mounjaro in the US, for instance ...